Deals

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson's Disease
AlectorGenentech

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson’s Disease

Alector, Inc. (NASDAQ: ALEC) announced an exclusive global licensing agreement with Genentech, a member of Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), granting Genentech worldwide rights to develop and commercialize…

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCBiocytogen Pharmaceuticals

Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs

ADC / XDCCancer

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

CancerGenomics / NGS

MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection

CRO / CMO / CDMOLionco Pharmaceutical

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

Show More